Erickson JD, Eiden LE, Hoffman BJ
*Correspondence: Norlela Sukor, [email protected] This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Recent insights into mechanisms of beta-cell lipo- and glucolipotoxicity in Type 2 Diabetes
Two primary formsmyo-inositol and d-chiro-inositolappear in clinical literature, with myo-inositol showing greater research support for metabolic applications
The FDA simultaneously launched a dedicated compliance webpage for telehealth companies promoting compounded drugs, signaling this is now a sustained priority - not a one-time action
BPC-157 Nasal Spray is supplied for Research Use Only (RUO)